GlassScriptPhysician profile
Lorenzo H Suarez
NPI 1619935137
$5,580.05
in general payments reported to CMS, 2019-2025
47 companies · $590 in 2025
The $590 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $656 · 2020: $814 · 2021: $1,429 · 2022: $992 · 2023: $565 · 2024: $534 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,659 · Education: $30.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.66 |
| Education | $30.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,077.95 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $380.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $369.16 | 2019-2025 | Airsupra, Farxiga |
| Corcept Therapeutics | $351.29 | 2020-2025 | Korlym |
| Lilly USA, LLC | $321.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $252.30 | 2019-2025 | Verquvo, Belsomra |
| Novo Nordisk INC | $226.84 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $213.80 | 2019-2024 | |
| Amgen INC. | $207.42 | 2019-2024 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.49 | 2019-2023 | Trulance |
| Abbvie INC. | $164.09 | 2019-2024 | Vraylar, Linzess, Viberzi |
| Boston Scientific Corporation | $157.11 | 2021-2022 | |
| Pfizer INC. | $132.34 | 2019-2024 | |
| Esperion Therapeutics, INC. | $123.79 | 2021-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $114.69 | 2022-2024 | Givlaari, Oxlumo, Amvuttra |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lorenzo Suarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.